To study the interaction between factor Vlll and von Willebrand factor (vWF), binding experiments were performed using immobilized plasma vWF. Plasma was obtained from healthy donors and from patients with severe hemophilia A. For normal and hemophilic vWF, the dissociation constants (kd) for binding of factor Vlll to vWF were 0.21 & 0.04 and 0.22 2 0.05 nmol/L, respectively. At saturation, the stoichiometry was one factor Vlll molecule per 50 vWF monomers. In gel-filtration experiments, vWF was saturated by 23 times more factor VIII. However, when this FVIII-vWF complex was immobilized on microtiter plates, the ratio of factor Vlll/vWF decreased to the same ratio as in the solid-phase binding assay. To exclude any effect of antibody binding, colloidal ACTOR VI11 IS AN X-LINKED gene product that accelerates the activation of factor X by factor IXa in the coagulation process.' A deficiency of factor VI11 results in hemophilia A, a bleeding disorder affecting 1 in 10,000 males.2 In plasma, factor VI11 is bound to von Willebrand factor (vWF), a glycoprotein that plays an essential role in hemostasis by promoting the attachment of platelets to the injured vessel wall.3 vWF circulates in plasma as a series of disulfide-bonded multimers with molecular-weight values up to 20 X lo6 d a l t o n~.~ In vivo, the survival of factor VI11 is strongly dependent on the formation of a noncovalent complex with vWF.'-' This is also shown by von Willebrand disease type Normandy (recently classified as type 2Ny), in which several amino acid substitutions cause an abnormal factor VIII-vWF interaction. I In vitro, complex formation was shown to protect factor VI11 against inactivation by activated protein C,I2,l3 and activation and inactivation by factor Xa. l4
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To study the interaction between factor Vlll and von Willebrand factor (vWF), binding experiments were performed using immobilized plasma vWF. Plasma was obtained from healthy donors and from patients with severe hemophilia A. For normal and hemophilic vWF, the dissociation constants (kd) for binding of factor Vlll to vWF were 0.21 & 0.04 and 0.22 2 0.05 nmol/L, respectively. At saturation, the stoichiometry was one factor Vlll molecule per 50 vWF monomers. In gel-filtration experiments, vWF was saturated by 23 times more factor VIII. However, when this FVIII-vWF complex was immobilized on microtiter plates, the ratio of factor Vlll/vWF decreased to the same ratio as in the solid-phase binding assay. To exclude any effect of antibody binding, colloidal ACTOR VI11 IS AN X-LINKED gene product that accelerates the activation of factor X by factor IXa in the coagulation process.' A deficiency of factor VI11 results in hemophilia A, a bleeding disorder affecting 1 in 10,000 males.2 In plasma, factor VI11 is bound to von Willebrand factor (vWF), a glycoprotein that plays an essential role in hemostasis by promoting the attachment of platelets to the injured vessel wall.3 vWF circulates in plasma as a series of disulfide-bonded multimers with molecular-weight values up to 20 X lo6 d a l t o n~.~ In vivo, the survival of factor VI11 is strongly dependent on the formation of a noncovalent complex with vWF.'-' This is also shown by von Willebrand disease type Normandy (recently classified as type 2Ny), in which several amino acid substitutions cause an abnormal factor VIII-vWF interaction. I In vitro, complex formation was shown to protect factor VI11 against inactivation by activated protein C,I2,l3 and activation and inactivation by factor Xa. l4 The binding site for vWF on factor VI11 is located on the amino-terminal region of the light Studies with monoclonal antibodies (MoAbs) that inhibit the interaction have further localized this domain on factor VI11 to amino acids 1670-1684'' and 1673-1689.'* Recently, the presence of an additional binding site on the carboxyl-terminal region of the factor VI11 light chain has been suggested by binding studies using a fusion protein consisting of gluthation Stransferase and the C2 domain of factor VIII.l9 On vWF, a major factor VI11 binding site resides within the 34-kD amino-terminal tryptic fragment and, more specifically, gold particles with a diameter of 15 nm were coupled to purified vWF. This vWF-gold complex remained immunoreactive toward polyclonal and monoclonal antibodies, and was able to bind factor VIII, specifically, saturably, and reversibly. After incubation of vWF-gold with factor VIII, unbound and bound factor Vlll were separated by centrifugation. Binding isotherms of these fluid-phase binding experiments indicated a kd of 0.32 2 0.09 nmol/L and a stoichiometry of -0.5 factor Vlll molecule per vWF monomer. We conclude that vWF-binding to a surface, with or without an antibody, may induce a conformational change causing a dissociation of bound factor Vlll from vWF. 0 1995 by The American Society of Hematology.
within the first 272 amino acid residues of the mature vWF molecule,2'1.2' with a crucial role for residues 78 through 96 22 and a sequence around residue 53."
An intriguing issue remains the stoichiometry of the factor VIII-vWF complex in plasma. By convention, the amount present in 1 mL of normal human plasma is one unit for both proteins. For factor VIII, the reported specific activities range from 2,300 to 8,000 U/mg.'~,"-28 This corresponds to 0.1 to 0.4 pg/mL and -1 nrnol/L (assuming a molecular mass of 240 kD). vWF circulates in plasma at a concentration of -10 pg/mL. Because each monomer (with a molecular mass of 270 kD) can circulate as a dimer or a multimer with varying length, vWF is not commonly expressed in molar concentrations. Nonetheless, according to weight ratios, only one factor VI11 molecule is bound per 50 vWF monomers in plasma.2y This ratio remains unchanged in deficiency states such as von Willebrand disease,"' and concomitant increases of factor VI11 and vWF concentrations have been observed in disorders associated with acute-phase reactions."
Factor VI11 binding to vWF has been investigated using various techniques such as coating vWF directly on plasultra~entrifugation.'~ Using the first two techniques, binding affinities (kd) of 0.1 to 0.2 nmol/L were found, whereas the stoichiometry was one factor VI11 molecule per 50 to 100 vWF monomers-the same as in plasma. In contrast, the last two techniques showed a stoichiometry close to the theoretically possible; one factor VI11 molecule bound to one vWF monomer. However, it is important to note that in the ultracentrifugation experiments described by Lollar and Parker," porcine factors were used.
The plasma concentration of porcine factor VI11 and vWF are 2 to 3 pg/mL and 4 to 8 pg/mL, respectively, indicating that porcine vWF is already more than SO% saturated with factor VI11 in vivo."
In this report, we compared the binding of factor VI11 to vWF from normal human volunteers and to vWF from patients with severe hemophilia A using a solid-phase binding assay. To investigate the effect of surface adsorption oi'vWF on the complex formation with factor VIII, we used gelfiltration chromatography of the factor VIII-vWF complex for comparison. In addition, we used a third technique in which purified vWF was coupled to 15 For personal use only. on October 27, 2017. by guest www.bloodjournal.org From particles. This method was used to study the binding affinity (kd) and stoichiometry of the factor VIII-vWF complex in solution.
containing samples were added to the antibody-coated wells and incubated for 16 hours at 4°C. The precise amount of immobilized vWF in the solid-phase binding assay was determined by measuring the concentrations of vWF in the sample before and after binding to the antibody. By subtracting both concentrations, and taking into account the volume of the wells, the amount of vWF bound to the antibody was calculated. The antibody was not saturated in this assay, because higher signals could be obtained by using less diluted plasma. Endogenous factor VI11 was removed by incubating the wells for IO minutes with 150 mmol/L NaC1, 50 mmol/L TRIS-HCI, pH 7.4, 0.1% Tween-20, and 0.25 mom CaCI,. The plates were then washed and factor VIII was added in diluting buffer. After washing twice, bound factor VI11 was determined with the factor V111 Coatest, essentially according to the manufacturer's instructions. The CaC12 needed to assemble the tenase complex in this assay is supplied to the incubation mixture by starting the reaction with 25 mmol/L CaC12. Hydrolysis of the substrate was measured as the absorbance read at 405 nm, using a V-max microplate reader (Molecular Devices Corp, Menlo Park, CA). Factor VI11 concentration was determined by reference to a standard curve prepared with a normal plasma pool of 40 donors. Factor VI11 bound to BSA-coated wells (usually less then 10% of total binding) was subtracted from total binding to obtain specific binding.
Gel-jiltration chromarography. A Sephacryl 300 HR column (100 X I .6 cm) was equilibrated with Michaelis buffer (28.5 mmol/ L Na-barbital; 28.5 mmol/L Na-acetate, pH 7.4; I16 mmol/L NaCl; 0.5% BSA; 0.005% Triton-X-100; 1 mmol/L benzamidine; 0.02% NaN,). All gel-filtration experiments were performed at 4°C. Factor VI11 (1 00 pL, 25 UlmL) was either directly applied to the column, or after incubation (30 minutes) with 30 pL of normal or hemophilic plasma. Fractions were collected at a flow rate of 20 mLh and assayed for factor VI11 coagulant activity and vWF antigen using a one-stage coagulation assay42 (KC-l0 Coagulometer, Amelung GmbH, Lemgo, Germany) and a vWF-ELISA, respectively. After incubation with vWF, factor VI11 eluted in two peaks with a ratio of 23 in units per unit (0.5 factor VI11 molecule/vWF monomer) in the first peak (see Results). This saturated vWF was added to microtiter plates coated with MoAb RU-l, and incubated for 2 hours at 37°C. Thus, the amount of vWF bound was determined as described above. After binding, the amount of factor VI11 bound and in rhe supernatant was measured with the factor VI11 Coatest.
Preparation ofcolloidal gold. Colloidal gold solutions were prepared essentially as described?'.& Briefly, a 0.0125% solution of HAuC1, and a reducing mixture consisting of 0.2% tri-sodium citrate-dihydrate and 0.001% tannic acid in distilled water were prepared. The amount of tannic acid added to the reducing mixture determines the diameter of the gold particles. We used 0.001 % tannic acid to produce a homogeneous gold sol of 15 nm particles. Both solutions were warmed to 6 0 T , rapidly mixed, and stirred for 30 to 45 minutes at 60°C until the color changed to red. After boiling for S minutes, the gold sol was cooled and stored at 4°C until use.
Coupling of purijed vWF to colloidal gold. The binding of a protein to gold is pH-dependent, and in general, stable complexes can be obtained at a pH equal to or slightly higher than the isoelectric point of the protein inv0lved.4~ Because the reported isoelectric point of human vWF is between 5.7 and 5~9 ,~ the pH of the colloidal solution was adjusted to 6. I . Because the purified vWF was kept in 150 mmol/L NaCI, 50 mmow TRIS-HCI, pH 7.4, it was dialyzed against I O mmol/L TRIS-HCI, pH 6.1, to remove the salt. The minimal concentration of vWF required to stabilize the colloidal gold particles was determined with a concentration-variable adsorption isotherm as de~cribed."~ After conjugation, 1 % BSA (final concentration) was added for maximal stabilization. Subsequently, the vWFgold solution was centrifuged and resuspended three times to remove unbound vWF. All centrifugation steps were performed at 10,OOOg
For personal use only. on October 27, 2017. by guest www.bloodjournal.org From for 15 minutes. The vWF-gold conjugate was kept in 150 mmovL NaCI, 50 mmoVL TRIS-HCI, pH 7.4,0.1% Tween-20 and 1% BSA during purification steps and in binding experiments. In an attempt to verify the morphology of vWF after conjugation with colloidal gold, samples of the conjugate were adsorbed on EM-grids and examined in a JEOL-1200-CX electron microscope, as de~cribed.~' Factor VI11 binding to vWF-gold. Samples (80 to 100 pL) of vWF-gold at fixed concentrations were incubated with factor VI11 at increasing concentrations for 30 minutes at 37°C. After centrifugation, aliquots of the supernatant (10 to 25 pL) were removed and tested with a one-stage coagulation assay to determine the concentration of unbound factor VIII. Similar samples which were not centrifuged yielded the total amount of factor VIII. Bound factor VI11 was calculated by subtracting the unbound factor VI11 from the total amount of factor VIII. Binding isotherms were obtained by varying the concentration of factor VI11 (0 to 6 nmoUL) with a fixed concentration of vWF-gold (see Table 1 ). The time course of factor VI11 binding was studied in a similar manner, except that the factor VI11 concentration was constant (0.3 nmoVL) and exposure times ranged from 5 to 40 minutes. Control studies were performed in which clotting times were recorded with fixed amounts of factor VI11 in either the absence or presence of vWF-gold. Colloidal gold coated with 1% BSA was used to provide for nonspecific binding (usually <20% of total binding).
Calculations. In the solid-phase binding assays and in the experiments with vWF-gold, data were fitted employing a non-linear regression program (EnzFitter Software, Elsevier, Amsterdam, The net her land^)!^
RESULTS

Solid-phase binding assay.
The interaction between factor VI11 and vWF from healthy individuals and from patients with severe hemophilia A was studied by immobilizing plasma vWF with MoAb RU-1. In this assay, the presence of vWF does not interfere with factor VI11 determination." Previous reports indicated that factor VI11 binding to immobilized vWF was maximal after 30-60 minutes of incubation and could be reversed by the addition of 0.25 m o m CaC& or an excess of unbound vWF.'".I8 Normal and hemophilic vWF bound similarly to this antibody (-0.4 mU/well) as measured with a vWF-ELISA. Factor VI11 bound to this immobilized vWF in a dose-dependent manner. Scatchard analysis of binding data demonstrated the presence of a single class of binding sites with kd = 0.21 ? 0.04 nmom (n = 4) for normal pooled plasma (data not shown). For the 10 patients with hemophilia A, a p e a n kd of 0.22 2 0.05 nmoV L was found. For both normal and patient plasma, the number of factor VI11 binding sites was equivalent to -0.4 mU factor VI11 per well. Thus, the stoichiometry at saturation was -1 in units (one factor VI11 molecule/50 vWF monomers). A typical experiment with vWF from a single patient is shown in Fig 1. Several control experiments were performed. First, 6uri-fied vWF was directly coated to microtiter plates and factor VI11 binding was determined. Second, MoAb CLB-RAg 35 was used to immobilize vWF instead of MoAb RU-1. Third, factor VI11 was added to VW prior to adding the formed factor VIII-vWF-complexes to wells coated with MoAb RU-1. Fourth, rabbit immunoglobulins against mouse immunoglobulins were used (as a spacer for MoAb RU-1). In all these experiments, essentially the same binding characteris- tics were obtained (data not shown). To exclude a possible denaturing effect from washing with 0.25 m o m CaCI2, this step was omitted in a binding experiment with hemophilic vWF. Again, no differences in binding were observed. Finally, the amount of immobilized vWF was tested before and after binding experiments, with a peroxidase-conjugated anti-vWF antibody. This amount did not change during the binding experiments.
Gel-jiltration chromatography. Previous reports indicated that factor VI11 remains associated with vWF during gel-filtration chromatography on Sepharose CL-4B (fractionation range for globular proteins 6 X 1 O4 -2 X 1 O7 daltons), and that factor VI11 bound to vWF elutes in the void volume with the free factor VI11 eluting at larger elution With this technique, twelve times the amount of factor VI11 normally present in plasma was shown to bind to vWF.'~ In order to determine the effect of binding of a monoclonal antibody against vWF on preformed factor VIII-vWF complexes, vWF was "saturated" with factor VI11 and subjected to gel-filtration chromatography. After elution, fractions were added to antibody-coated wells. When 30 pL of normal citrate plasma (vWF antigen 1 U/mL) was applied to the column, vWF eluted in the void volume (-80 mL). Subsequently, recombinant factor VI11 (100 p], 25 nmoVL) was applied, which eluted in the included volume (-1 10 mL) with a recovery of 25% (Fig 2) . When the same amount of factor VI11 was preincubated with 30 p1 citrate plasma for 30 minutes and then applied to the column, factor VI11 eluted in two peaks, with a total recovery of -90%. In the first peak, the ratio of factor VIIYvWF was 23 2 3 (n = 3) in unitdunits (0.5 factor VI11 molecule/vWF monomer), whereas in the second peak only free factor VI11 was found. This value was constant in the first 4-5 fractions of the peak. However, conclusions concerning the binding of factor VI11 according to the multimeric distribution of vWF were not possible because of the elution of free factor VI11 in the later
Elution volume (mL) fractions of this peak. The same results were obtained when hemophilic plasma was used (data not shown). In a similar experiment, MoAb 418 (400 nmoVL, final concentration) directed against vWF was added to a sample of citrate plasma and incubated for 15 minutes, and then factor VI11 was added. In the presence of MoAb 418, which blocks the factor VIII-vWF interaction, factor VI11 eluted in a single peak in the included volume, as in the absence of vWF (not shown). Thus, the factor VI11 eluting in the void volume represents factor VI11 specifically bound to vWF. In contrast, preincubation of purified vWF with MoAb RU-1 or CLB-RAg 35 had no effect on factor VI11 binding. Aliquots (100 pL) from the first peak (Fig 2) were added to microtiter plates coated with MoAb RU-l and incubated for 2 hours at 37°C. A double vWF-ELISA (see above) revealed that approximately 30% of the vWF binds during this incubation. After binding, the supernatant was removed and assayed for factor VI11 activity with a chromogenic assay. After washing, the bound factor VI11 was determined in the same way. The factor VI11 activity in the supernatant was 65 t 6% (n = 3) of the initial amount, whereas bound factor VI11 was decreased to a factor VIIYvWF ratio of 1.3 2 0.6 (n = 3) in unitdunits (1 factor VI11 molecule/40 vWF monomers). These results suggest that factor VI11 dissociates from vWF upon binding of vWF to an antibody on a surface.
Labeling of vWF with colloidal gold. To investigate the binding of factor VI11 to human vWF without the interference of antibodies or surfaces, purified vWF was coupled to colloidal gold particles with a diameter of 15 nm. In a concentration-dependent adsorption isotherm4', the curve showed optimal stabilization at a vWF concentration of 20 pg/mL. Therefore, purified vWF (25 U/mL) in 10 mmol/L TRIS-HC1, pH 6.1, was diluted 10 times in a solution of 15 nm colloidal gold (pH 6.1), and mixed by gentle inversion.
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After 15 minutes at room temperature, BSA was added to a final concentration of 1%. After washing by centrifuging three times, the amount of unconjugated vWF was less than 1% the amount of conjugated vWF. When analyzed by electron microscopy, vWF conjugated with colloidal gold showed characteristics that resembled that of unconjugated native vWF, ie, some vWF multimers were depicted as elongated strands, whereas most were in a ball-of-yam configuration.48
Factor VIII binding to v WF-gold. First, the time needed for binding of factor VI11 to vWF was determined. Factor VI11 (0.3 nmol/L) was incubated with vWF-gold (0.1 U/mL) at various time intervals (5 to 40 minutes), followed by centrifugation. Complex formation was already maximal after 5 minutes (data not shown). Although the binding possibly proceeds during the centrifugation step, this suggests that factor VI11 binding to vWF is a rapid process.
To compare the binding affinity of vWF-gold and nonlabeled vWF, samples with different mixtures of both (total vWF concentration, 0.125 U/mL) were incubated with factor VI11 (0.125 nmoVL). After 30 minutes, the samples were centrifuged and the residual amount of factor V1II:C in the supernatant was determined. Figure 3 shows that factor VI11 binding corresponded to the percentage vWF-gold, demonstrating that free vWF and vWF-gold had the same affinity for factor VIII.
To investigate whether binding of factor VI11 to vWFgold was reversible, factor VI11 (1.0 nmoVL) was incubated with vWF-gold (0.1 U/mL). After 30 minutes, increasing amounts of nonconjugated vWF (up to a 100-fold excess) were added and incubated for 3 hours. We hypothesized that when factor VI11 dissociates from vWF-gold it either remains free or reassociates with nonconjugated vWF. Either way, factor VI11 will remain in the supernatant during centrifugation. After centrifugation, the remaining factor VI11 in the supernatant was measured with an ELISA and compared with initial values for each sample. Here, we preferred an ELISA for the detection of factor VIII, because the high salt concentration used in this ELISA (1 m o m NaCl) dissociates all factor VIII-vWF complexes and, thus, eliminates any potential disturbance by the excess of nonlabeled vWF. As shown in Fig 4, nonlabeled vWF effectively displaced previously bound factor VIII. After 3 hours and with a 100-fold excess of nonlabeled vWF, -80% displacement had occurred. Thus, factor VI11 binding to vWF-gold appears essentially reversible under these conditions.
To assess the binding affinity and stoichiometry of factor VI11 binding to vWF-gold, increasing amounts of factor VI11 were added to vWF-gold and incubated for 30 minutes at 37°C. For each concentration, two samples were prepared, one of which was not centrifuged to provide for the total amount of factor VIII. Control experiments showed that the one-stage coagulation assay was not disturbed by exposure to colloidal gold particles (data not shown). After centrifugation, the residual factor VI11 in the supernatant was quantified, and the amount of factor VI11 bound was calculated. As shown in Fig 5, a saturable , dose-dependent binding was observed. Several experiments were performed with different concentrations of vWF-gold (see Table 1 ). The data obtained were in agreement with a model describing the interaction of factor VI11 with vWF with one class of binding 
3.00
Factor VI11 free (nmol/L) sites. The dissociation constant was 0.32 rfr 0.09 nmol/L (n = 4), and the maximum number of factor VI11 binding sites was equivalent to -27 U factor VIIY1 U v W F gold (0.5 factor VI11 molecule/vWF monomer).
DISCUSSION
In this study, we investigated the binding of factor VI11 to vWF with three different techniques. First, a solid-phase binding assay was used, in which vWF was immobilized on a surface with a MoAb. We showed that normal v W F binds factor VI11 with a dissociation constant (kd) of 0.21 2 0.04 nmoVL. At saturation, an apparent factor VIIYvWF stoichiometry of about 1 U factor VIIYl U vWF (equivalent with one factor VI11 molecule per 50 v W F monomers) was found. These data are consistent with previously reported re- Increasing amounts of factor Vlll (0 to 6 nmol/L) were incubated with vWF-gold for 30 minutes at 37°C. After centrifugation (10,OOOg. 15 minutes) the remaining amount of factor Vlll in the supernatant was determined. Scatchard transformation of data was performed using a nonlinear regression program. Stoichiometry data were converted from U/U to molecule/monomer with the following molecularweight values and plasma concentrations: factor VIII, 240 kD and 0.2 pg/mL; vWF, 270 kD and 10 pg/mL.
For personal use only. on October 27, 2017. by guest www.bloodjournal.org From sUlts.10.11.18.33.M Because no information was available concerning the binding of factor VIII to vWF from patients with hemophilia A, we investigated this interaction with vWF from 10 patients with this bleeding disorder. Both the dissociation constant and stoichiometry were comparable with normal vWF. The high-affinity association between factor VI11 and v W F from patients with hemophilia A found in this study may be important in achieving clinically effective factor VI11 levels in those patients. With the present prophylaxis consisting of monoclonally-purified and recombinant factor VIII,51*52 little or no vWF is infused into the patient.
As a consequence, factor VIII is dependent on endogenous vWF, with which it has to form a complex in order to be protected against proteolytic degradati~n.'~.'~ To assess whether binding of vWF to an antibody or a surface influences the binding of factor VIII, we used gelfiltration techniques. In the presence of vWF, factor VIII eluted in two peaks; in the first peak, 23 U factor VIII coeluted with l U vWF (0.5 factor VIII molecule/vWF monomer). Zucker et a l l 2 performed similar studies with BaS0,-treated plasma as a source of vWF, in agreement with our findings, they also found that vWF can be loaded with much more factor W1 than present in plasma. When we incubated this FVIII-vWF complex with an antibody directed to vWF coated on microtiter plates, considerably less factor W1 was bound (-1 factor VIII molecule/40 vWF monomers). In addition, the same stoichiometry was found when factor VIII was incubated with purified vWF directly coated on microtiter plates. Thus, a clear distinction in factor VIII binding to vWF in solution and vWF immobilized to a surface is evident from these experiments.
As a third technique we used colloidal gold to label purified vWF. Binding of proteins to colloidal gold is a complex phenomenon, mediated by hydrophobic and ionic interactions. This method has been used to label factor fibrinogen: ' and various other pr0teins.4~ We used 15-nm colloidal gold to label purified human vWF, given the dimensions of monomeric vWF of -60 ~m . 3~
The structure of vWF may be an advantage, because multimeric proteins have a larger number of possible contacts with a metal surface.47 Factor VI11 binding was not influenced by labeling with colloidal gold (Fig 3) . Also, factor VIII bound to vWF-gold was shown to dissociate in the presence of an excess of nonlabeled vWF (Fig 4) . Thus, nonlabeled vWF can compete with vWF-gold not only in the initial formation of the factor VIIIvWF-gold complex, but also after the FVIII-vWF complex has been formed. This is consistent with our previous observation in vivo, that radiolabeled factor VI11 in complex with lower multimeric vWF was redistributed over all multimeric forms of vWF, after infusion into patients with hemophilia A.54
The discrepancy in binding of factor VIII to vWF in the solid-phase binding assay and vWF in solution is remarkable. In this study, two different methods were used to estimate factor VI11 activity: the factor VIII Coatest assay and the one-stage coagulation assay. However, control experiments showed that both assays gave the same results when recombinant factor VIII is used (data not shown). Kaufman et a l S 5 used both assays to detect recombinant factor VI11 in culture media and also found similar results. Possibly, the conformation of vWF alters upon binding directly to plastic or via an MoAb. However, in gel-filtration experiments, preincubation of vWF with two MoAbs against vWF that were also used in solid-phase binding assays, had no effect on factor VI11 binding. These results suggest that the decrease in binding capacity of vWF is caused by vWF binding to a surface, either directly or indirectly with an antibody. Another explanation may be that factor VIII binds to vWF via additional binding sites (which are presently unknown), and that this weak interaction is disturbed by binding of vWF to a surface, or during the washing procedure.
In this report, one single class of binding sites for factor with one conformation found in only 1% of the native vWF subunits having the capacity to bind factor VIII. In contrast, our results with vWF-gold showed a stoichiometry of 0.5 factor VIII molecule/vWF monomer, suggesting that at least 50% of the vWF subunits can participate in the interaction with factor VIII. Lollar and Parke?5 studied the interaction of porcine factor VIII with porcine vWF by analytical velocity sedimentation and also found that all factor VIII-binding sites are accessible in the vWF multimer. However, because human and porcine factor VIII differ markedly in plasma concentration (0.1 to 0.2 pg/mL v 2 to 3 pg/mL, respectively), those results may not be directly applicable to humans.
In plasma, the ratio of FVIIUvWF is -1:50.29 It is not known which process regulates this ratio in vivo; however, several mechanisms may be of importance. The main production site of factor VIII is the liver,'7 whereas vWF is produced in endothelial cells58.59 and megakaryocytes.@' The site of complex formation is not precisely known, but is probably close to the liver because vWF was shown to play an important role in biosynthesis of factor VI11 by promoting the assembly of the factor VI11 heavy and light chains upon secretion from Chinese hamster ovary cells.61 Interestingly, factor VI11 secreted by those cells forms a complex with vWF added to the culture medium with the same stoichiometry as in plasma, and this is also the required ratio for optimal reconstitution of isolated factor VI11 heavy and light chains?' In addition, although more factor VIII can be bound to vWF, we previously found that the ratio found in plasma is needed to obtain full protection against proteolytic degradation by For personal use only. on October 27, 2017. by guest www.bloodjournal.org From activated protein C." Thus, processes at the site of synthesis and complex formation, as well as proteolytic breakdown in the plasma, may both regulate the factor VIIVvWF ratio in vivo.
In conclusion, our data show that the binding affinity of vWF from patients with hemophilia A for factor VI11 is similar to normal vWF. The solid-phase binding assay gives the same value for the stoichiometry of the factor VIIYvWF complex as observed in plasma. In contrast, 50% of the vWF monomers can bind a factor VI11 molecule when gelfiltration techniques are used or when vWF is labeled with colloidal gold. The dissociation constant for factor VI11 and vWF in solution is 0.32 2 0.09 nmol/L. Labeling with colloidal gold may prove valuable in studying the interaction of vWF with its other ligands, such as heparin, collagen, and platelet glycoproteins. 
